Organovo Holdings Inc

NASDAQ:ONVOUnited States

Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.

Contact Information

Headquarters

Suite 110, 6275 Nancy Ridge DriveSAN DIEGO, CA, United States 92121

Phone

858-550-9994

Fax

302-636-5454

Executives

Executive Chairman of the Board, Principal Executive Officer, Corporate Secretary

Keith Murphy

President, Chief Financial Officer

Tom Hess

Director - Discovery Biology, Director

Vaidehi Joshi

Lead Independent Director

Douglas Cohen

Independent Director

David Gobel